| Description |
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities[1][2].
|
| Related Catalog |
|
| Target |
Human Endogenous Metabolite
|
| In Vitro |
Enterodiol (0-100 μM; 24-72 hours) results in an apoptosis rate of up to 40% in CT26 cells. Enterodiol shows no cytotoxicity toward RAW264.7 macrophages[1]. Enterodiol (0-100 μM; 24-48 hours) also suppresses the migration of CRC cells in a concentration-dependent manner. The phosphorylation of ERK, JNK, and p38 is down-regulated with Enterodiol treatment. Enterodiol (0-100 μM; 48 hours) decreases the expression levels of anti-apoptotic proteins in CRC cells[1].
|
| In Vivo |
Enterodiol (1 mg/kg; intra-tumor injection method; once every other day until day 32) suppresses tumor markedly[2]. Animal Model: 4-8 weeks old female BALB/c nude mice[2] Dosage: 1 mg/kg Administration: Intra-tumor injection method; once every other day until day 32 Result: A significant reduction in the tumor volume in the experimental groups compared to the PBS group.
|
| References |
[1]. Shin MK, et al. Apoptotic effect of enterodiol, the final metabolite of edible lignans, in colorectal cancer cells. J Sci Food Agric. 2019;99(5):2411-2419. [2]. Liu H, et al. Enterolactone has stronger effects than enterodiol on ovarian cancer. J Ovarian Res. 2017;10(1):49. Published 2017 Jul 24.
|
